• Ebru Atalar, İsmail Doğan, Kevser Gök, Serdar Can Güven, Yüksel Maraş, Gülay Güleç Ceylan, and Sükran Erten.
• Division of Rheumatology, Department of Internal Medicine, Ankara City Hospital, Ankara, Turkey.
• Turk J Med Sci. 2022 Jan 1; 52 (2): 494504494-504.

Background/AimAnti IL-1 therapy is useful in suppressing attacks in FMF patients with colchicine resistance, however, it is not certain whether subclinical inflammation can sufficiently be inhibited with anti-IL-1 therapy in FMF patients with amyloidosis.Materials And MethodsForty-six FMF patients receiving anti-interleukin-1 therapy and 36 healthy control patients were compared in terms of laboratory parameters. Also, FMF patients were further divided into two groups; those with amyloidosis and those without it, and these subgroups were compared to each other in terms of clinical and laboratory findings.ResultsIn comparison between the FMF and healthy control groups, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) level, and red cell distribution width (RDW) level were detected to be higher and hemoglobin level lower in the patient group. Within the FMF patient group, the ESR, CRP, fibrinogen, RDW, and NLR values were significantly higher in the subgroup with amyloidosis in comparison to the subgroup without amyloidosis.ConclusionAnti-interleukin-1 therapy could not fully suppress the subclinical inflammatory parameters when compared to healthy individuals.© TÜBİTAK.

6 keywords...

hide…